10-DAB-III is a vital intermediate in the semi-synthetic production of Paclitaxel and docetaxel (breast, ovarian, lung cancers) and related anti-cancer drugs.
- Selling Markets: India, Nepal, Europe
- Market Highlights: Demand driven by the oncology sector’s continued reliance on taxane-based chemotherapy drugs. Pharmaceutical manufacturers in Europe and India represent a strong and consistent buyer base.
- For 10-DAB III, the global API market is $450–600 million, growing 8–10% annually.
- Opportunity: Establish long-term supply partnerships with global pharmaceutical companies focusing on oncology formulations.
Reviews
There are no reviews yet.